Transcend Capital Advisors, LLC Bio Atla, Inc. Transaction History
Transcend Capital Advisors, LLC
- $1.44 Billion
- Q3 2024
A detailed history of Transcend Capital Advisors, LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Transcend Capital Advisors, LLC holds 10,000 shares of BCAB stock, worth $5,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$5,300% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BCAB
# of Institutions
66Shares Held
17.5MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$1.41 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$1.33 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$999,1830.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$984,8330.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$463,2600.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $19.2M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...